Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

Autor: Morel KL; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia., Germán B; Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, United States of America., Hamid AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America., Nanda JS; Division of Hematology and Oncology Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America., Linder S; Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands., Bergman AM; Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands., van der Poel H; Division of Urology, Netherlands Cancer Institute, Amsterdam, Netherlands., Hofland I; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, Netherlands., Bekers EM; Division of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Trostel SY; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America., Burkhart DL; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America., Wilkinson S; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America., Ku AT; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America., Kim M; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, United States of America., Kim J; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, United States of America., Ma D; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States of America., Plummer JT; Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, United States of America., You S; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, United States of America., Su XA; Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, United States of America., Zwart W; Division of Oncogenomics, Oncode Institute, Netheralnds Cancer Institute, Amsterdam, Netherlands., Sowalsky AG; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America., Sweeney CJ; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia., Ellis L; Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, United States of America.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer.

Autor: German B, Singh JN, Fonseca MA, Burkhart DL, Sheahan A, Bergom H, Morel KL, Beltran H, Hwang JH, Lawrenson K, Ellis L

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Feb 02. Date of Electronic Publication: 2024 Feb 02.

Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment.

Autor: Giafaglione JM; Molecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, USA., Crowell PD; Molecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, USA., Delcourt AML; Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA, USA., Hashimoto T; Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA, USA., Ha SM; Department of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA, USA., Atmakuri A; Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA, USA., Nunley NM; Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Dang RMA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA., Tian M; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA., Diaz JA; Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA, USA., Tika E; Laboratory of Stem Cells and Cancer, WEL Research Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium., Payne MC; Department of Mechanical & Aerospace Engineering, University of California, Los Angeles, Los Angeles, CA, USA., Burkhart DL; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Li D; Fred Hutchinson Cancer Center, Seattle, WA, USA., Navone NM; Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA., Corey E; University of Washington, Seattle, WA, USA., Nelson PS; Fred Hutchinson Cancer Center, Seattle, WA, USA., Lin NYC; Department of Mechanical & Aerospace Engineering, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA.; Institute for Quantitative and Computational Biosciences, University of California, Los Angeles, Los Angeles, CA, USA., Blanpain C; Laboratory of Stem Cells and Cancer, WEL Research Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium., Ellis L; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Boutros PC; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Vector Institute, Toronto, Ontario, Canada.; Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA.; Eli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, Los Angeles, CA, USA., Goldstein AS; Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA, USA. agoldstein@mednet.ucla.edu.; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. agoldstein@mednet.ucla.edu.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. agoldstein@mednet.ucla.edu.; Eli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, Los Angeles, CA, USA. agoldstein@mednet.ucla.edu.; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA. agoldstein@mednet.ucla.edu.

Publikováno v: Nature cell biology [Nat Cell Biol] 2023 Dec; Vol. 25 (12), pp. 1821-1832. Date of Electronic Publication: 2023 Dec 04.

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.

Autor: Morel KL; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Sheahan AV; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Burkhart DL; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Boufaied N; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada., Liu Y; Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Center University Health Network, Toronto, Canada., Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cañadas I; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA., Roehle K; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Heckler M; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Calagua C; Department of Medicine, Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Ye H; Department of Pathology, University of California at Los Angeles, Los Angeles, CA, USA., Pantelidou C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Galbo P; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA., Panja S; Department of Health Informatics, Rutgers School of Health Professionals, Newark, NJ, USA., Mitrofanova A; Department of Health Informatics, Rutgers School of Health Professionals, Newark, NJ, USA.; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA., Wilkinson S; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Whitlock NC; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Trostel SY; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hamid AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kibel AS; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Choudhury AD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sweeney CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Einstein DJ; Hematology and Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dougan SK; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Sowalsky AG; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., He HH; Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Center University Health Network, Toronto, Canada., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Balk SP; Hematology and Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Loda M; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Labbé DP; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada.; Division of Urology, Department of Surgery, McGill University, Montréal, Canada., Olson BM; Departments of Hematology and Medical Oncology and Urology, Emory University School of Medicine, Atlanta, GA, USA., Ellis L; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA. Leigh.Ellis@cshs.org.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Leigh.Ellis@cshs.org.; Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. Leigh.Ellis@cshs.org.; Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Leigh.Ellis@cshs.org.; Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA. Leigh.Ellis@cshs.org.

Publikováno v: Nature cancer [Nat Cancer] 2021 Apr; Vol. 2 (4), pp. 444-456. Date of Electronic Publication: 2021 Mar 22.

Myc linked to dysregulation of cholesterol transport and storage in nonsmall cell lung cancer.

Autor: Hall Z; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom zoe.hall@imperial.ac.uk.; Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom., Wilson CH; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom.; Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom., Burkhart DL; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Ashmore T; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom., Evan GI; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom., Griffin JL; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom.; Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.

Publikováno v: Journal of lipid research [J Lipid Res] 2020 Nov; Vol. 61 (11), pp. 1390-1399. Date of Electronic Publication: 2020 Aug 04.